November 16, 2010, Pasadena, California -- Customized Therapeutics LLC (CTL) has been awarded two grants by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of the company’s two leading molecular diagnostic tests in the pipeline.
The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer. Recipients are eligible for grants or tax credits through the QTDP by carrying out research for the purpose of securing approval from the U.S. Food and Drug Administration for products that address an area of unmet medical need or prevent, detect or treat chronic or acute diseases or conditions.
Oluwole Odujinrin MD, President and CMO says “the QTDP funding will assist CTL in developing products that help physicians identify the best course of treatment that improves survival rates, reduces toxicities and enhances the Quality of Life of patients with catastrophic illnesses especially cancer.”
CTL’s molecular diagnostic products are treatment responsiveness indicator assays for breast, prostate and ovarian cancers. There are currently no products that identify the likelihood of response to chemotherapy for these cancers and CTL products will be the ‘first to market’ products for these indications.
Customized Therapeutics is also building a pipeline of novel therapeutics, and drug delivery systems through in-house development and in-licensing of technologies with high clinical potential. These products cater to the unmet need for improved and targeted therapies with low systemic toxicities and high efficacy profile. The company’s unique product development paradigm directly addresses the needs of patients receiving care in the clinics, by streamlining drug discovery, translational development and innovative clinical trial designs. This reduces product development cost and time to market.
CTL’s lead therapeutic candidates include fully human monoclonal antibodies for treatment of B-Cell malignancies, with potential to be more safe and efficacious than currently used monoclonal antibodies such as Rituximab (Rituxan).
About the company: Customized Therapeutics LLC was designed as a fully integrated biopharmaceutical company from its inception in 2004, replete with its own research and products on the market or in clinical trials that it acquires from others. The unique Business Proposition for CTL is planning for product development that begins with the needs of physicians and clinics caring for patients in communities all over the country.
“We seek inventions in research institutions with high likelihood of successful commercialization into useful diagnostics and therapies for the clinics. In the process we believe we have a greater likelihood to “cure” cancer and other catastrophic illnesses in humans. This is the reverse of traditional drug development paradigm that finds cures in mice with subsequent search for potential utility in humans through Phase II Clinical trials. This is what makes CTL unique”, says Dr. Odujinrin.
Customized Therapeutics 3452 E. Foothill Blvd. # 315 Pasadena, CA 91107 Ph: 626.584.6045 Fax: 626.584.6031
Website: http://www.ctlglobal.com
